AstraZeneca PLC (AZN) Announces Positive Results From a Prespecified Interim Analysis of the I CAN Phase III Trial

AstraZeneca PLC (NYSE:AZN) is one of the best stem cell therapy stocks to buy. AstraZeneca PLC (NYSE:AZN) announced on April 21 that positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris met its primary endpoint, exhibiting a statistically significant and clinically meaningful reduction of proteinuria. This was based on a 24-hour urine protein creatinine ratio at week 34 in adults with immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Management stated that the primary endpoint of change from baseline in estimated glomerular filtration rate (eGFR) will be measured at week 106.

AstraZeneca’s (AZN) Dividend: Resilient, Predictable, and Built on Innovation

AstraZeneca PLC (NYSE:AZN) also reported that the safety profile observed in the trial remained consistent with the known profile of Ultomiris, with no new safety concerns identified. According to the management, the company will seek accelerated approval in key markets and will present these results at a forthcoming medical meeting. IgAN is a rare, inflammatory disease of the kidneys that can result in chronic kidney disease (CKD) and progress to end-stage kidney disease (ESKD).

AstraZeneca PLC (NYSE:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and primary care physicians, and is involved in exploring novel immuno-oncology treatment approaches. AstraZeneca PLC (NYSE:AZN) distributes its products and services through local representative offices and distributors.

While we acknowledge the risk and potential of AZN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AZN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.